Skye Bioscience, Inc.
For the period ended Aug 12, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 12, 2026 · Filed Aug 14, 2026
Contents
EX-99.1 · About Skye Bioscience
About Skye Bioscience
Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biotechnology company. Its lead program has been nimacimab, a negative allosteric modulating antibody that peripherally inhibits the CB1 receptor, developed for weight loss in patients with obesity or overweight and evaluated in the CBeyond Phase 2a trial. Additional information is contained in Skye's periodic reports filed with the SEC. For more information, visitwww.skyebioscience.com.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.